AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE

Rhea-AI Summary

Amgen (NASDAQ:AMGN) is scheduled to present at the 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 10:40 a.m. ET. Susan Sweeney, senior vice president of Global Marketing, Access and Capabilities, will lead the presentation. The event will be available via live webcast for media, investors, and the public.

Details and replay options will be found on Amgen's website under Investors. As a leading biotechnology firm, Amgen focuses on significant unmet medical needs and aims to enhance health outcomes through innovative therapies. The company is recognized in major indices, including the Dow Jones Industrial Average.

THOUSAND OAKS, Calif., Feb. 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023. Susan Sweeney, senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.  

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.

For more information, visit Amgen.com and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube.  

CONTACT: Amgen, Thousand Oaks
Jessica Akopyan, 805-447-0974 (media) 
Arvind Sood, 805-447-1060 (investors) 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-2023-svb-securities-global-biopharma-conference-301743390.html

SOURCE Amgen

FAQ

When is Amgen's presentation at the 2023 SVB Securities Global Biopharma Conference?

Amgen's presentation is on February 14, 2023, at 10:40 a.m. ET.

Who will represent Amgen at the 2023 SVB Securities Global Biopharma Conference?

Susan Sweeney, senior vice president of Global Marketing, Access and Capabilities, will represent Amgen.

Will Amgen's presentation be available for public viewing?

Yes, the presentation will be available via live webcast for the media, investors, and the public.

Where can I find the replay of Amgen's conference presentation?

The replay will be available on Amgen's website under the Investors section for at least 90 days after the event.

What is Amgen known for in the biotechnology industry?

Amgen is known for developing innovative human therapeutics focused on significant unmet medical needs.